Xeris Bundle
What makes Xeris a unique biopharma story?
Founded as Strongbridge Biopharma in 2005, the company rebranded to Xeris in 2018, a name from the Greek word for 'dry.' This shift highlighted its foundational focus on creating stable, non-aqueous injectable drugs that break from traditional cold-chain constraints. This innovative approach has been central to its identity and commercial strategy.
The company's journey from a formulation concept to a publicly traded entity is a testament to strategic focus. Its growth is underscored by a recent FDA approval and a market cap near $335 million in early 2025. Discover the competitive dynamics in our Xeris Porter's Five Forces Analysis.
What is the Xeris Founding Story?
Xeris Biopharma was officially founded in 2005 by key scientific founder Dr. Steven Prestrelski, originally operating under the name Strongbridge Biopharma. The foundational vision addressed the critical instability of peptide and protein-based injectable therapeutics, which created significant treatment burdens. Initial funding was secured from private investments and venture capital to support the long biotech development journey.
Xeris Biopharma Founding Story
The founding team, which included seasoned pharmaceutical executives, built the original business model around two proprietary technology platforms: XeriSol and XeriJect. These platforms were designed to create non-aqueous, ready-to-use liquid formulations, solving a persistent problem in drug delivery that is detailed further in our analysis of Xeris's target market.
- Founded in 2005, with foundational technology developed by Dr. Steven Prestrelski.
- Operated as Strongbridge Biopharma until a pivotal 2018 restructuring.
- Initial focus was on stabilizing otherwise unstable injectable drugs.
- Secured early-stage funding through venture capital and private investments.
Xeris SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Xeris?
The period following its 2018 rebranding to Xeris Biopharma marked a phase of accelerated growth for the company. This crucial expansion was fueled by its first FDA product approval and a successful public offering, which provided the capital to build a commercial infrastructure and expand its team to over 200 employees by 2023, supporting its strategic focus on endocrinology and rare diseases.
First Commercial Product and Public Offering
A pivotal moment in the Xeris Biopharma timeline was the U.S. FDA approval of Gvoke® in September 2019 for severe hypoglycemia. The company then executed a successful initial public offering on the Nasdaq under the ticker 'XERS', raising crucial capital to fund the marketing strategy of Xeris and its commercialization efforts.
Strategic Portfolio Expansion
Building on its initial success, Xeris Pharmaceuticals expanded its portfolio with the FDA approval of Recorlev® for Cushing's syndrome in December 2021. This was quickly followed by the approval of Ogluo® for hypoglycemia in adults in March 2022, demonstrating the company's focused product development history in endocrinology.
Building Commercial Infrastructure
A key strategic decision was building a specialized sales force targeting endocrinologists and diabetes specialists. Under the leadership of CEO Paul R. Edick, the team expanded from a research-focused group to over 200 employees by 2023 to support these direct commercial operations and ongoing R&D for its ready-to-use injectables.
Platform Strategy and Market Entry
The company's early growth leveraged its proprietary technology platform to in-license and reformulate existing drugs, enhancing their stability profiles. This strategy facilitated not only the development of its core products but also enabled market expansion into Europe, solidifying its position in the global pharmaceutical landscape.
Xeris PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Xeris history?
Xeris Pharmaceuticals history is defined by groundbreaking innovation in ready-to-use injectables, marked by consecutive FDA approvals and strong revenue growth, yet challenged by the significant cash burn inherent to commercial-stage biopharma companies.
| Year | Milestone |
|---|---|
| 2019 | The FDA approved Gvoke, the company's first commercial product and a ready-to-use glucagon injection for severe hypoglycemia. |
| 2021 | Xeris secured FDA approval for Recorlev, a treatment for endogenous Cushing's syndrome, expanding its endocrinology portfolio. |
| 2022 | The company launched Ogluo in the U.S., a ready-to-use glucagon for the treatment of severe hypoglycemia in diabetes patients. |
| 2023 | Xeris reported a 47% year-over-year increase in total revenue, reaching $63.9 million, largely driven by Gvoke's commercial performance. |
| 2024 | The FDA approved a pediatric indication for Ogluo, expanding its market potential, and the company secured a $75 million private placement. |
The core of the Xeris Biopharma timeline is its proprietary formulation platform, a technological marvel protected by over 100 global patents. This innovation enables the stabilization of peptides and proteins into liquid, ready-to-use injectables, overcoming a major industry hurdle.
Proprietary Formulation Platform
This patented technology is the foundation of the Xeris company history, allowing for the creation of stable, liquid formulations of drugs that traditionally required reconstitution. It solves significant problems in drug delivery, convenience, and emergency use.
Gvoke HypoPen
As the first ready-to-use glucagon auto-injector, Gvoke represented a major leap forward in hypoglycemia rescue care. Its approval and commercial success became a primary driver for Xeris Pharmaceuticals stock and company valuation.
Product Portfolio Expansion
Innovation extended beyond technology into rapid commercial execution, launching three products—Gvoke, Recorlev, and Ogluo—in a four-year span. This built a diverse revenue base from Xeris Pharmaceuticals products.
Despite its innovative products, Xeris has navigated the financial challenges typical of growth-stage biopharma, including substantial net losses. The company has addressed these hurdles through strategic financing and operational streamlining to ensure long-term viability.
Financial Sustainability
Xeris reported a net loss of $61.6 million in 2023 despite strong revenue growth. To extend its cash runway, the company executed a $75 million private placement of convertible notes in early 2024.
Pandemic Product Launches
Launching key products like Gvoke during global COVID-19 disruptions required highly adaptive and virtual commercial strategies. This tested the company's ability to reach healthcare providers and patients under extraordinary circumstances.
Strategic Refocusing
Under the leadership of CEO Paul R. Edick, Xeris divested its Rare Endocrinology patient support program in late 2023. This decision streamlined operations and refocused resources on core commercial and development assets for greater capital efficiency, a key part of the Brief History of Xeris.
Xeris Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Xeris?
The Xeris company history is marked by strategic transformation and product innovation, evolving from its 2005 founding as Strongbridge Biopharma into a leader in ready-to-use injectables, with a future focused on achieving profitability by 2026.
| Year | Key Event |
|---|---|
| 2005 | The company is founded as Strongbridge Biopharma, establishing its initial focus. |
| 2018 | It rebrands to Xeris Biopharma and completes a reverse merger to become publicly traded on Nasdaq under XERS. |
| 2019 | FDA approves Gvoke®, a ready-to-use glucagon injection for severe hypoglycemia. |
| 2021 | FDA approves Recorlev® for the treatment of endogenous Cushing’s syndrome. |
| 2022 | FDA approves Ogluo® (dasiglucagon) injection for severe hypoglycemia in adults. |
| 2023 | Xeris achieves record annual revenue of $163.9 million, demonstrating significant commercial traction. |
| 2024 | FDA approves Ogluo® for use in pediatric patients, expanding its market potential. |
Commercial Expansion
Maximizing the potential of approved products like Gvoke and Ogluo is a primary focus, with Q1 2025 showing Gvoke prescriptions grew 35% year-over-year. The strategy centers on expanding payer coverage and driving prescription volume to fuel top-line growth.
Pipeline Development
Xeris is leveraging its proprietary technology platform to build a robust pipeline, including XP-8121 for bi-hormonal pumps and XP-8122, a ready-to-use pramlintide. This R&D effort aims to address complex solubility challenges in new therapeutic areas.
Path to Profitability
Under the leadership of CEO Paul R. Edick, management's stated goal is to achieve profitability by 2026. This will be supported by disciplined operational spending and the continued strong revenue growth demonstrated in recent quarters.
Strategic Partnerships
The company actively pursues strategic partnerships and out-licensing agreements to extend its technology's reach. This aligns with the broader Mission, Vision & Core Values of Xeris to become the leading platform for stable liquid formulations.
Xeris Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Xeris Company?
- What is Growth Strategy and Future Prospects of Xeris Company?
- How Does Xeris Company Work?
- What is Sales and Marketing Strategy of Xeris Company?
- What are Mission Vision & Core Values of Xeris Company?
- Who Owns Xeris Company?
- What is Customer Demographics and Target Market of Xeris Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.